Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group-Reference-Cited by-同舟云学术

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

Published:2014-12-18 Issue:2 Volume:169 Page:188-198
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Purroy Noelia¹,Bergua Juan²,Gallur Laura¹,Prieto Julio²,Lopez Luis A.³,Sancho Juan M.⁴,García-Marco Jose A.⁵,Castellví Josep⁶,Montes-Moreno Santiago⁷,Batlle Ana⁸,de Villambrosia Sonia Gonzalez⁸,Carnicero Fernando²,Ferrando-Lamana Lucía⁹,Piris Miguel A⁷,Lopez Andrés¹

Affiliation:

1. Department of Haematology; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universitat Autònoma de Barcelona (UAB); Barcelona Spain

2. Department of Haematology; Hospital San Pedro Alcántara; Cáceres Spain

3. Department of Haematology; Hospital Royo Villanova; Zaragoza Spain

4. Department of Haematology; Hospital Germans Trias i Pujol; Badalona Spain

5. Department of Haematology; Hospital Puerta del Hierro; Madrid Spain

6. Department of Pathology; Hospital Universitari Vall d'Hebron; Barcelona Spain

7. Department of Pathology; Hospital Universitario Marqués de Valdecilla; IFIMAV; Santander Spain

8. Cytogenetics Unit; Department of Haematology; Hospital Universitario Marqués de Valdecilla; IFIMAV; Santander Spain

9. Department of Pathology; Hospital San Pedro Alcántara; Cáceres Spain

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13273/fullpdf

Reference37 articles.

1. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology,1999

2. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy;Choi;Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,2009

3. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

4. Regression models and life tables;Cox;Journal of the Royal Statistical Society,1972

5. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium;Jong;Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology,2007

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B-cell lymphoma patients;Frontiers in Oncology;2024-06-05

2. Acute Pancreatitis Revealing a Diagnosis of Diffuse Large B-Cell Lymphoma;ACG Case Reports Journal;2024-03-28

3. PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B‑cell lymphoma patients;2023-11-07

4. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022);Clinical and Translational Oncology;2023-06-08

5. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma;Expert Review of Anticancer Therapy;2023-01-24